Despite the known link between antibiotic use and antimicrobial resistance (AMR), antibiotic consumption is likely to increase worldwide by 200 percent between 2015 and 2030 says a new report; increasing the very real threat that AMR presents.
AMR resistance is not only of concern to governments and healthcare systems, it should also be on corporate risk radars. The loss of antibiotics could have an impact on workforce health, with bacterial infections being able to spread within workplaces.
The new Center For Disease Dynamics, Economics & Policy (CDDEP report), ‘The State of the World's Antibiotics in 2021’, presents extensive data on global antimicrobial use and resistance as well as drivers and correlates of antimicrobial resistance, based on CDDEP's extensive research and data collection through ResistanceMap, a global repository that has been widely used by researchers, policymakers, and the media.
Since the first State of the World's Antibiotics report in 2015, antimicrobial resistance has leveled off in some high-income countries but continues to rise in many low- and middle-income countries (LMICs), where access to antibiotics has risen with increases in gross domestic product per capita. Per capita antibiotic consumption in LMICs is lower than in high-income countries, despite a higher infectious disease burden; however, consumption rates are rapidly converging. These trends reflect both better access to antibiotics for those who need them and increases in inappropriate antibiotic use.
An important driver of resistance is antibiotic use in humans and in terrestrial and aquatic animals raised for human consumption. Global antibiotic consumption in humans increased by 65 percent between 2000 and 2015, whereas consumption in animals is expected to increase by 11.5 percent between 2017 and 2030. If nothing changes to alter these trajectories, antibiotic consumption is likely to increase worldwide by 200 percent between 2015 and 2030.
The approaches to addressing AMR are to reduce the need for antibiotics (through prevention of infections), to reduce the use of antibiotics (by better use of diagnostics and antibiotic stewardship), and to innovate to find new methods of disease prevention and treatment. All three strategies are needed so that a strong arsenal of effective antibiotics can be maintained.